Pharmed Limited, established in 1946 and headquartered in Bangalore, India, is recognized as one of the fastest-growing pharmaceutical companies in the country. The company focuses on manufacturing a wide range of evidence-based pharmaceutical and nutraceutical products, primarily targeting specialized therapy areas such as women's health, orthopedic health, pain management, and general healthcare. Its commitment to quality and innovation has led to the introduction of several "first-time in India" brands
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 359.6 | 425.99 | 436 | - |
| Cost of Material Consumed | - | - | - | - |
| Gross Margins | - | - | - | - |
| Change in Inventory | - | - | - | - |
| Employee Benefit Expenses | 97.79 | 129.79 | - | - |
| Other Expenses | - | - | - | - |
| EBITDA | - | - | - | - |
| OPM | - | - | - | - |
| Other Income | 9.45 | 9.98 | 9.98 | - |
| Finance Cost | 0.36 | 0.3 | 0.36 | - |
| D&A | 2.32 | 3.27 | 3.27 | - |
| EBIT | 55.02 | 43.1 | 43.1 | - |
| EBIT Margins | - | - | - | - |
| PBT | 55.02 | 43.1 | 43.1 | - |
| PBT Margins | - | - | - | - |
| Tax (2021) | - | - | - | - |
| PAT | 42.3 | 33 | 9.36 | - |
| NPM | - | - | - | - |
| EPS | - | - | - | - |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | - | - | - | - |
| Net Profit Margin | 11.76% | 12.08% | 7.77% | - |
| Earning Per Share (Diluted) | ₹76.54 | ₹98.27 | ₹76.54 | - |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 0.86 | 0.86 | 0.86 | - |
| Reserves | 230.19 | 198.74 | - | - |
| Borrowings | - | - | - | - |
| Trade Payables | 20.24 | 24.06 | - | - |
| Other Liabilities | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| PBT | - | 55.02 | 43.1 | - |
| OPBWC | - | 49.08 | 37.27 | - |
| Change in Receivables | - | -0.93 | -1.57 | - |
| Change in Inventories | - | -6.25 | 1.22 | - |
| Change in Payables | - | 12.56 | -12.66 | - |
| Other Changes | - | 0.3 | 8.44 | - |
| Working Capital Change | - | 5.68 | -4.57 | - |
| Cash Generated From Operations | - | 53.87 | 38 | - |
| Tax | -14.12 | -8.99 | -10.03 | - |
| Cash Flow From Operations | - | 39.75 | 29.01 | - |
| Purchase of PPE | -41.97 | -1.13 | -1.13 | - |
| Sale of PPE | 0.55 | 0.06 | 0.06 | - |
| Cash Flow From Investment | -49.48 | -18.94 | -18.94 | - |
| Borrowing | - | 0 | 0 | - |
| Divided | -3.01 | -0.36 | -0.36 | - |
| Equity | - | - | - | - |
| Others From Financing | - | - | - | - |
| Cash Flow from Financing | -3.31 | -1.87 | -1.87 | - |
| Net Cash Generated | -54.78 | -18.94 | -8.2 | - |
| Cash at the Start | - | - | - | - |
| Cash at the End | - | - | - | - |
